StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
GHC.MI$5.26+1.14%
Fair $5.26+0.0%

GHC.MI

Garofalo Health Care S.p.A.

Healthcare / Medical Care FacilitiesMilan

$5.26

+0.06 (+1.14%)

Fairly Valued+0.0%Fair Value $5.26Fund rank 35/100 · Data gapFallback financials|
SA 54/C
F-Score: 7/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 23% · confianza 25%

FCF escenarios

weak_data · normalized FCF $15.5M · quality 67.7/100

Data gap 35/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 69/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

54/100

C

Piotroski

7/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · GHC.MILocal privado en este navegador · Garofalo Health Care S.p.A.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$464M

P/E

21.9x

↑

EV/EBITDA

9.2x

↓

ROE

6.9%

↑

Gross Margin

84.6%

↑

Debt/Equity

0.67

↑
52-Week Range$5
$4$6

TradingView lightweight chart

GHC.MI price, volumen y niveles de valoración

Último $5.320Periodo +38.2%
Fair value: $5.260

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+14.9%

FCF CAGR

-18.7%

FCF margin

3.2%

FCF / Net income

0.66x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $485.1M · net income $23.4M · FCF $15.5M

2022-FY → 2025-FY

Gross margin

84.6%-1.4% pts

Operating margin

11.4%-0.3% pts

Net margin

4.8%-1.9% pts

FCF margin

3.2%-5.8% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$485.1M$485.1M$467.8M$366.1M$320.0M
Net Income$23.4M$23.4M$21.7M$20.8M$21.4M
EBITDA$72.7M$72.7M$69.9M$60.7M$49.9M
EPS0.260.260.240.180.24
Gross Margin84.6%84.6%85.0%86.4%86.0%
Operating Margin11.4%11.4%11.7%12.7%11.7%
Net Margin4.8%4.8%4.6%5.7%6.7%
Balance Sheet
Debt/Equity0.670.670.710.760.63
Current Ratio1.151.15———
Cash Flow
Free Cash Flow$15.5M$15.5M$13.4M$32.9M$28.9M
Returns
ROE6.9%6.9%6.7%7.0%7.7%
Valuation
P/E21.9221.9222.5824.7216.21
EV/EBITDA9.249.249.919.889.83
P/B1.371.371.521.321.24
Growth & Yield
Revenue Growth3.7%3.7%27.8%14.4%—
EPS Growth8.3%8.3%33.3%-25.0%—
Dividend Yield1.8%1.8%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

21.5%

exigente

EPS terminal req.

$0.47

Spread vs growth

-13.2%

5Y implied EPS CAGR

16.8%

exigente

EPS terminal req.

$0.56

Spread vs growth

-8.4%

10Y implied EPS CAGR

13.3%

razonable

EPS terminal req.

$0.91

Spread vs growth

-5.0%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +3.7%

Total return

+3.7%

Start / end P/E

21.7x → 20.5x

EPS bridge

0.24 → 0.26

Residual

-0.5%

EPS growth+8.3%
Multiple rerating-5.9%
Dividend+1.8%
Residual / FX / buybacks / cross-term-0.5%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.